Aclarion

Aclarion P/B

The P/B (Price-to-Book Ratio) of Aclarion (ACON) as of Nov 4, 2026 is 0.27. In the previous year, P/B (Price-to-Book Ratio) was 3.54 — a change of -92.44% (lower).

P/B

0.27

YoY

-92.44%

Last updated:

P/B (Price-to-Book Ratio) of Aclarion is 2025 0.27 . P/B (Price-to-Book Ratio) of Aclarion was 2024 3.54 . It decreases by -92.44% lower compared to the previous year.

The Aclarion P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
-2.02 USD
Jan 1, 2020
-0.49 USD
Jan 1, 2021
-0.60 USD
Jan 1, 2022
1.54 USD
Jan 1, 2023
-4.72 USD
Jan 1, 2024
3.54 USD
Jan 1, 2025
0.27 USD
The Aclarion P/B history
YEARP/BYoY
0.27-92.44%
3.54-175.05%
-4.72-405.77%
1.54-357.39%
-0.60+23.64%
-0.49-75.97%
-2.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aclarion Stock analysis

What does Aclarion do? Aclarion, Inc. generates revenue through its proprietary biomarker technology and signal processing software, which transforms raw Magnetic Resonance Spectroscopy (MRS) data into metabolic biomarkers for clinical use. The company's products are utilized by physicians to differentiate between painful and nonpainful lumbar spine discs, leveraging augmented intelligence in post-processing algorithms to quantify biomarker data and produce individualized ratio metrics against normative datasets. The firm targets healthcare providers focused on chronic low back pain treatment, offering solutions that optimize clinical decision-making through metabolic analysis. Aclarion's technology is centered on Magnetic Resonance Spectroscopy (MRS) and its proprietary biomarker, designed to assist physicians in determining disc-related pain in the lumbar spine. The company's signal processing software and expert system convert raw spectral MRS data into clear, actionable biomarkers, enabling tailored treatment approaches for chronic low back pain patients. By focusing exclusively on this clinical application, Aclarion serves a specialized segment of healthcare providers seeking advanced diagnostic tools for spinal conditions. Aclarion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aclarion stock

P/B (Price-to-Book Ratio) of Aclarion is 0.27 in 2025.

P/B (Price-to-Book Ratio) of Aclarion changed from 3.54 to 0.27, representing a -92.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Aclarion since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Aclarion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Aclarion

All Key Metrics — Aclarion